Author: hwa

TOKYO, Japan, Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. (Honda) today announced that the company will make organizational and operational changes, effective April 1, 2026, in order to sustainably offer the joy and freedom of mobility all around the world through its mobility products and services.In 2020, with the aim of solidifying its existing business while preparing for future growth, Honda separated two key research and development functions — the development of production models and research on future technologies — enabling each group to focus on its roles. This initiative generated solid results including contribution to Honda business and the enhancement of technological competitiveness.With the global business environment surrounding Honda changing faster than expected, the company will further strengthen its ability to grasp market and technology trends more accurately and deliver the original technologies and new value of Honda to the market at the optimal timing. Toward this goal, Honda will make changes to the organizational structure of the Automobile Development Operations and the Automobile Operations.Moreover, the Motorcycle and Power Products Operations will also undergo some organizational changes to ensure future growth. Details of the organizational changes effective April 1, 20261) Consolidation of automobile R&D functions at Honda R&D Co., Ltd.The R&D functions of the Automobile Development Operations and the SDV Business Development Unit within the Automobile Operations will be transferred to Honda R&D Co., Ltd., the R&D subsidiary of Honda.Since 2020, the two key research and development functions — the development of production models and research on future technologies — have been operated separately so that each group can focus on its roles. However, in order to further enhance the strengths of its products, Honda will make organizational changes to build a structure where the entire process — from the selection of technology themes through product market launches — is viewed as one integrated flow to drive the entire process at speed, while flexibly responding to the changes in business environment. Through this change, Honda R&D will be further advanced as a R&D organization capable of continuing to create compelling products, through which Honda will further increase its competitiveness.2) Reorganization of Automobile Operations The Automobile Business Strategy Unit and Sales Unit will be reorganized into the Business Strategy Unit and Regional Business Unit, which will be newly created effective April 1, 2026. In addition, the business functions currently being served by the SDV Business Development Unit will be reorganized into the new Business Strategy Unit, and the SDV Business Development Unit will be disbanded.Through these organizational changes, for the earliest improvement of the profitability of its automobile business, Honda will 1) enhance its product planning and sales capabilities in light of market dynamics and customer needs, and 2) strengthen the competitiveness of its products from the mid- to long-term perspectives. 3) Reorganization of Motorcycle and Power Products Operations As the electrification strategy for motorcycle and power products business has transitioned into the execution stage, sales, business strategy and product development functions currently being served separately for electrification business and ICE (internal combustion engine) business will be integrated. Through the integrated management of electrification and ICE business, Honda will pursue optimal allocation of resources and continue initiatives toward carbon neutrality, while striving to ensure the continuous creation of increasingly competitive products. Through these organizational changes, Honda will further accelerate ongoing initiatives for its corporate transformation through electrification and new value creation, through which Honda will strive to establish a more distinctive presence as “a company society wants to exist” even in the era of electrification and intelligent technologies. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - KS Energy Co., Ltd. ("KS Energy"), a renewable energy business company and Hitachi, Ltd. (TSE:6501, “Hitachi”) agreed on February 6 to collaborate on the development and operation of an Extra-High Voltage Grid Battery Energy Storage System*1 within Kumamoto Prefecture, as well as the development and operation of power trading businesses. Hitachi will provide project development support for KS Energy's development of the project and jointly promote the development and operation of this battery energy storage system (tentative name)*2 . Additionally, KS Energy will also explore the introduction of a power trading support system planned for development by Hitachi.This initiative will support stable power supply in the Kyushu region and contribute to achieving carbon neutrality.*1 Extra-High Voltage Grid Battery Energy Storage System: Large-scale battery storage facilities directly connected to the power grid (such as transmission lines) with a capacity of 2,000 kW or more.*2 Power Trading Support System: A power trading support system for operators managing large-scale grid-connected storage batteries. It supports traders' daily operations comprehensively—from bid planning and market transactions to submitting plans to OCCTO—across both the supply-demand adjustment market and the wholesale electricity market. System development also incorporates collaboration with other companies, such as bid plan optimization services. This contributes to improved profitability through trading based on optimal bid plans and streamlines routine daily tasks like plan submission.BackgroundRenewable energy generation fluctuates due to weather changes and other factors, significantly impacting the power supply-demand balance. Particularly in the Kyushu region, where renewable energy adoption is advancing, output curtailment occurs frequently when generation exceeds demand. Securing balancing power to stabilize the power grid is an urgent priority. Furthermore, as the policy framework for promoting renewable energy shifts from the FIT (Feed-in Tariff) system to the FIP (Feed-in Premium) system, power generators are now required to develop their own electricity trading capabilities to formulate strategies for selling electricity in the power market. Against this backdrop, the importance of "aggregators" – entities that consolidate and control energy resources to adjust supply-demand balance – is growing. They are expected to contribute to the effective utilization and stable supply of renewable energy by engaging in both the electricity market and the power trading market.To address this situation, KS Energy, established in January 2024 with full investment from Higo Bank, Ltd. (part of the Kyushu Financial Group), has adopted a policy to contribute to stabilizing power supply as a regional energy company, aiming to make the entire Kyushu region a leading area for renewable energy circulation. Meanwhile, Hitachi has a long history in the power sector, providing a wide range of advanced solutions from energy storage systems to transmission and distribution infrastructure and grid protection devices.Through this collaborative effort, both companies will combine their respective strengths. By developing and operating energy storage facilities and engaging in power trading, they aim to achieve carbon neutrality in the Kyushu region.Initiative DetailsKS Energy and Hitachi have decided to jointly develop and operate battery energy storage system in the Kyushu region. This initiative contributes to stabilizing local power supply by charging and discharging in response to electricity demand-supply balance, thereby providing balancing power.1. Nation's First Extra-High Voltage Battery Energy Storage System project launched by a regional bank group This marks the first instance nationwide of a bank subsidiary's renewable energy business company undertaking a grid energy battery business in the extra-high voltage range. Through this initiative, we aim to contribute to stable power supply. Additionally, KS Energy is considering managing the power trading for the storage facility in-house. The plan involves handling the entire operational process: forecasting electricity market prices, creating power generation (charging/discharging) plans for the batteries, controlling the storage facility, and monetizing through market transactions. In the future, leveraging its operational expertise in storage facilities and collaborating with Higo Bank, KS Energy will enhance support for power generators and provide financing support to storage facility developers. This will enable the delivery of services extending beyond the financial sector, promote efficient electricity usage within local communities, and contribute to achieving regional carbon neutrality and decarbonization.2. Joint Promotion of Project Development from the Early Stage Leveraging Hitachi’s extensive experience in battery energy storage systems, Hitachi and KS Energy will jointly promote the development of energy storage facilities. The Hitachi Group will work together to promote project development through to operational launch. This includes cooperation from grid connection application discussions with transmission and distribution operators to applications and procedures with relevant ministries and agencies, provision of business feasibility evaluation information, supply of Hitachi Energy-manufactured PCS, and project management covering equipment design, procurement, and installation. Hitachi will sustainably support KS Energy's stable operations of the storage facility.3. Collaboration in Power Trading Business To stably utilize rapidly expanding renewable energy, the need for aggregation functions that balance electricity supply and demand is growing. KS Energy is considering introducing Hitachi's planned power trading support systemto achieve efficient energy resource utilization and aim for stable power supply. Under Hitachi's Lumada 3.0 initiative, the company is deploying "HMAX by Hitachi" (hereinafter HMAX), a next-generation AI solution suite that tackles the most complex challenges facing social infrastructure. This is achieved by combining vast data from both physical and digital assets with advanced AI enhanced by Hitachi's unique deep domain knowledge. In the electric power trading area as well, Hitachi will realize services that optimize the operation of storage battery assets and maximize market value, and aim to deploy them as HMAX.Future DevelopmentsKS Energy and Hitachi will collaborate to achieve both the mainstreaming of renewable energy as a primary power source and stable supply through the development of battery energy storage system and enhanced aggregation functions, working together toward realizing regional carbon neutrality.Overview of Grid-Connected Storage FacilityStorage Facility Name : (Provisional name) KSE Kumamoto Battery Energy Storage SystemStorage Facility Location (Planned) : Within Kumamoto PrefectureRated Output/Rated Capacity (Planned) : 50,000 kW / 112,880 kWhScheduled Start of Operation : January 2029 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and CAMBRIDGE, Mass., Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China.The Priority Review and Approval Procedure was implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened.If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration every two weeks in a hospital setting. The potential approval of SC-AI would expand the option for patients and care partners to receive LEQEMBI treatment at home. The injection time for each autoinjector (250 mg injection) is approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion and nurse monitoring, while streamlining the overall AD treatment care pathway.Eisai estimates that there were 17 million patients with MCI or mild dementia due to AD in China in 2024, which is expected to increase with the aging of the population. LEQEMBI was launched in China in June 2024 and has been delivered in the private market. Furthermore, LEQEMBI has been included in the newly introduced “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), which took effect in January 2026, under new Chinese government policies that support the development of and access to innovative medicines. Based on the Commercial Insurance Innovative Drug List, Commercial insurance companies will develop insurance products covering LEQEMBI.Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In China, Eisai will distribute the product and conduct information provision activities through specialized Medical Representatives.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 7 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China. Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About ProtofibrilProtofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.For more information, visit https://www.eisai.com/news/2026/pdf/enews202608pdf.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 9, 2026 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) will exhibit at MWC Barcelona 2026, the world's largest mobile-related exhibition, held from Monday, March 2 to Thursday, March 5, 2026, in Barcelona, Spain.NEC booth renderingUnder the theme of "Building an AI-Native Society," NEC will showcase its initiatives for the social implementation of hardware and software to realize advanced communications in an AI-Native society in the Beyond 5G/6G era.On March 2, the first day of the exhibition, Dr. Juergen Quittek, Head of NEC Laboratories Europe, will participate as a panelist in a session titled "AI and Us: What Are We Really Building Toward?" He will discuss the expanding applications of AI, drawing on NEC's efforts in this field.Furthermore, the NEC exhibition booth will showcase the latest vRAN-compatible Radio Units (RUs) for enhancing the efficiency of 5G networks, low-power RU amplifier modules, AI automation for realizing network automation through software, and initiatives for energy efficiency.About the Panel SessionDate & Time: Monday, March 2, 10:45 – 11:45 (CET)Venue: Hall 6 Johnson StageTitle: Conference "AI and Us: What Are We Really Building Toward?"Speaker: Dr. Juergen Quittek, Head of NEC Laboratories EuropeURL: https://www.mwcbarcelona.com/agenda/sessions/5965-ai-and-us-what-are-we-really-building-towardExhibition BoothLocation: Hall 2 Stand 2B18Exhibits: 5G/6G vision, latest vRAN-compatible 5G base station equipment, power amplifier modules for 5G base station equipment, optical device products, AI automation, etc.Going forward, NEC will continue to contribute to the realization of an AI-Native society by implementing advanced communication equipment and virtualization technologies throughout the world.About NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit https://www.nec.com, and follow us on LinkedIn and YouTube. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, Feb 9, 2026 - (ACN Newswire via SeaPRwire.com) – CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is pleased to announce a triumph in winning two prestigious awards as 2026 unfolds, recognizing its cybersecurity and continuous innovation capabilities. CITIC Telecom CPC’s AI-driven Security Operations Centre (AI SOC) is honored “Best AI SOC Service Provider” in “IT PRO Corporate Choice Award 2025” from the well-known IT media . In addition, two security experts of CITIC Telecom CPC have won two accolades in “Internet and Cloud Services” sector of “Cyber Security Professional Awards 2025” organized by the Hong Kong Police Force (Cyber Security and Technology Crime Bureau, CSTCB).Mr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC, said, “2026 marks the 25th anniversary of CITIC Telecom CPC. Our tagline “Innovation Never Stops for 25 Years. Empowering a Smarter Future” embodies 25 years of continuous innovation, driving the creation of a more secure and highly efficient digital future. We strive to enhance our solutions to address the evolving needs of our customers and drive innovation in an ever-changing landscape. We empower enterprises to leverage innovative security solutions to elevate operational efficiency, supporting their “Going Global” and “Coming to China” efforts with tailored strategies, and being the trusted DICT service partner of multinational corporations and enterprise customers. We are honored to receive the “Best AI SOC Service Provider” Award and the “Cyber Security Professional Awards 2025”, a testament to our enduring commitment to cybersecurity innovation and the technical expertise of our talented professional team, driving groundbreaking solutions development through technological innovation.”CITIC Telecom CPC proudly presents the following accolades:“IT PRO Corporate Choice Award 2025”- “Best AI SOC Service Provider”“Cyber Security Professional Awards 2025” - 2 Accolades in “Internet and Cloud Services” sectorCITIC Telecom CPC clinches “Best AI SOC Service Provider” of“IT PRO Corporate Choice Award 2025”Garners IT PRO Corporate Choice Award 2025CITIC Telecom CPC’s AI SOC has been bestowed with the "Best AI SOC Service Provider" of the ‘IT PRO Corporate Choice Award 2025” for the first time. This award honors CITIC Telecom CPC's customer-focused innovative security solutions that address enterprises’ evolving needs in an increasingly complex cyber threats environment. It also serves as a testament to CITIC Telecom CPC's unwavering dedication to delivering top-tier AI-driven security services, which are widely valued by enterprise customers across different industries. CITIC Telecom CPC’s cutting-edge SOC technologies have been highly acclaimed in the industry. The company was honored one of the top three most trusted Security Operations Centers (SOCs) in Hong Kong according to the “IT PRO Corporate SOC Survey[1]” conducted by in April 2025, recognizing its technical expertise and market leadership in security operations.Leveraging groundbreaking and robust AI technologies, AI SOC significantly enhances the overall efficiency of SOC. As the core of AI SOC, SIEM-MiiND is a self-built and managed intelligent security information and event management (SIEM) platform. It utilizes big data and intelligent technologies to boost the detection capabilities of AI SOC, optimize rule sets, improve response capabilities, provide AI-powered chatbot and user-friendly security dashboard, enabling cost-effective and robust security protection for enterprises, and reshaping the future cybersecurity model. Two Cybersecurity Experts Win Two Accolades in Cyber Security Professional Awards 2025Organized by the Hong Kong Police Force (CSTCB), Cyber Security Professional Awards 2025 aims to recognize outstanding industry talent, foster innovation, and strengthen public-private collaboration to jointly enhance Hong Kong’s cybersecurity. Two security experts of CITIC Telecom CPC received two accolades in “Cyber Security Professional Awards 2025” Thomas KT Wong, Director of Security Services Delivery & Operation, and Sung Liu, Security Specialist of CITIC Telecom CPC received Silver and Merit Awards respectively in the “Internet and Cloud Services” sector of “Cyber Security Professional Awards 2025”. Both of them have over 10 years of network security experience. Thomas KT Wong is instrumental in managing the SOCs of CITIC Telecom CPC. He leads a team of security experts to provide 24/7 security monitoring and incident response services, thereby safeguarding enterprise cybersecurity. Sung Liu is responsible for core technologies support, providing comprehensive and practical security solutions to address enterprise pain points. The two awardees have extensive industry experience, profound knowledge and technical expertise, facilitating CITIC Telecom CPC in maintaining its competitive edges in the cybersecurity market and further reaffirming its professionalism and commitment to the cybersecurity sector.About CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SD-WAN gateways, 20 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises. We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.For more information, please visit www.citictel-cpc.com.Media Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536 Email: catherine.yuen@citictel-cpc.com[1] The survey was conducted online by IT PRO via email questionnaire to more than 12,000 mid to senior-level executives in local enterprises in April 2025. Source (Chinese only): https://itpromag.com/2025/05/16/it-pro-soc-result Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO//SINGAPORE, Feb 9, 2026 - (JCN Newswire via SeaPRwire.com) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan's only international payment brand, today announced a new collaboration with RESORTS WORLD AT SENTOSA PTE. LTD. (RWS), targeted at Japanese tourists. The partnership with RWS is designed to enhance the travel experience for Japanese visitors to Singapore.Located on Sentosa, Singapore’s premier resort island, Resorts World Sentosa is one of the nation’s leading integrated lifestyle destinations, welcoming millions of local and international visitors annually across its attractions, dining, entertainment and lifestyle offerings. This collaboration aims to curate meaningful experiences that enhance every stage of the visitor journey for Japanese guests.JCB and RWS today launched exclusive privileges for Japan-issued JCB cardmembers visiting Singapore’s leading integrated resort. Under this collaboration, eligible JCB cardmembers booking online will enjoy:1. Up to 20% savings on selected attractions and accommodation experiences; and2. Dining and retail privileges at participating outlets within RWS attractions.These privileges are designed to enhance every stage of the visit, from iconic attractions to hotel stay, delivering seamless, rewarding experiences for international guests. Full details, as well as terms and conditions including participating outlets are available on https://www.rwsentosa.com/en/promotions/jcb.“Our launch of this programme comes at an opportune time, amid a steady rise in Japanese tourist arrivals to Singapore. Visitor numbers from Japan in 2025 have exceeded 2024 while remaining below pre-pandemic levels. Through collaboration with leading attractions such as RWS, we aim to offer Japanese travellers more compelling reasons to visit, enjoy, and extend their stay in Singapore,” said Hiroko Michishita, Managing Director, JCB International Asia Pacific.Jenny Wang, Acting Senior Vice President, Resort Sales and Marketing, RWS, commented: “We are pleased to partner with JCB to deepen our engagement with Japanese travellers and strengthen RWS’s presence in the Japan market. Through this collaboration, we aim to welcome JCB cardmembers to experience Singapore and RWS through a curated range of attractions, dining and lifestyle experiences, complemented by exclusive privileges and joint marketing initiatives between two trusted brands. Beyond this campaign, our partnership with JCB reflects our longer-term commitment to building sustained relevance in Japan, positioning Resorts World Sentosa as Asia’s leading lifestyle destination that continues to inspire repeat visitation, deeper engagement and enduring brand affinity among Japanese guests.”JCB cardmembers can learn more via the following page:https://www.specialoffers.jcb/en/promotion/yokosoJCB_Singapore/About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 71 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 175 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: http://www.global.jcb/en/ContactAnna TakedaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 9, 2026 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station is an anime exhibition site focused on Japanese anime content, which has developed a devout fan base around the world. The facility attracts visitors of all ages and has welcomed 253,236 guests from Japan and overseas (as of January 18, 2026).©Taiki Kawakami, Fuse, KODANSHA/ “Ten-Sura”Anime Tokyo Station regularly hosts special exhibitions for popular anime. From February 21 (Sat.) to May 24 (Sun.), 2026, it will hold the “That Time I Got Reincarnated as a Slime” Special Exhibition.This popular TV anime first aired in 2018 and has now reached its third season. The story follows Satoru Mikami, an office worker who is suddenly reincarnated as a slime in another world after being caught up in an incident. Taking on the name Rimuru Tempest, he embarks on a series of adventures in this new realm. At present, in addition to the fourth season of the TV anime that is slated to air, a second theatrical release, “That Time I Got Reincarnated as a Slime: The Movie – Tears of the Azure Sea,” is also scheduled for release this February.This special exhibition will look back on the story through the third season of the TV anime, featuring life-size character panels, character introductions, and a mosaic depicting the scene where Rimuru and Veldora become friends, created using stills from the anime. Visitors can also enjoy interactive digital content, creating an experience unique to Anime Tokyo Station where they can fully immerse themselves in the world of the series.Come to Anime Tokyo Station and experience what the “That Time I Got Reincarnated as a Slime” Special Exhibition has to offer.“That Time I Got Reincarnated as a Slime” Special ExhibitionExhibition OverviewThe TV anime “That Time I Got Reincarnated as a Slime” first aired in 2018 and has grown into a beloved series spanning three seasons, with a fourth season slated to air. Additionally, “That Time I Got Reincarnated as a Slime: The Movie – Tears of the Azure Sea” is scheduled for release as well. This special exhibition will feature exhibits that allow visitors to experience the world of the series, including recreations of iconic scenes such as when Rimuru and Veldora become friends, as well as introductions to popular characters.Highlights of the ExhibitionExhibitsLife-size character panelsA mosaic depicting the scene where Rimuru and Veldora become friends, created using stills from the animeA look back at the story through stills and memorable lines Hands-on areasAR photo spot: Take a commemorative photo with Rimuru! And moreDatesFebruary 21, 2026 to May 24, 2026*Exhibition content is subject to change without notice. Details will be announced on the official website.Special exhibition URL: https://animetokyo.jp/en/archives/events/events56/About the SeriesWhat is “That Time I Got Reincarnated as a Slime”?“That Time I Got Reincarnated as a Slime” is an isekai anime series following a protagonist who is reincarnated as a slime in another world, using the skills he acquires along with his wits and courage to gather allies. The first season of the TV anime aired on TOKYO MX and other channels from October 2018 to March 2019.In 2021, TV anime Season 2 Part 1 aired from January to March, followed by the spin-off comic adaptation “Slime Diaries: That Time I Got Reincarnated as a Slime” from April to June, and TV anime Season 2 Part 2 from July to September, making for nine consecutive months of broadcasts. Then, on November 25, 2022, “That Time I Got Reincarnated as a Slime: The Movie – Scarlet Bond” was released nationwide, becoming a major hit with over one million admissions and box office revenue of 1.4 billion yen in Japan.To commemorate the 10th anniversary of the web novel “That Time I Got Reincarnated as a Slime,” the Tensura 10th Project launched on February 20, 2023. As part of this project, the all-new three-episode animation “That Time I Got Reincarnated as a Slime: Visions of Coleus” began streaming on November 1, 2023. On December 16, 2023, the series’ first large-scale event, That Time I Got Reincarnated as a Slime: Tensura 10th Live, was held at Mori no Hall 21 in Matsudo. Furthermore, the third season of the TV anime aired from April to September 2024. Following the final episode of Season 3, production of a second theatrical film and Season 4 of the TV anime was announced. “That Time I Got Reincarnated as a Slime: The Movie – Tears of the Azure Sea” is set to release on February 27, 2026.The original manga “That Time I Got Reincarnated as a Slime” (serialized in Kodansha’s Monthly Shonen Sirius / Manga: Taiki Kawakami, Original story: Fuse, Character design: Mitz Vah) is a comic adaptation of the popular web novel of the same name by Fuse, which surpassed 1 billion page views on the user-generated novel publishing website “Shosetsuka ni Naro.” The combined worldwide circulation of the manga, novels, and spin-off works has exceeded 56 million copies (as of June 2025).* “Shosetsuka ni Naro” is a registered trademark of HinaProject Inc.Tensura Portal Site: ten-sura.comOfficial X: @ten_sura_anime / Official Instagram: tensura_official / Official TikTok: @ten_sura_animeVenue OverviewName:Anime Tokyo Station (also known as "Anime Tokyo")Location:Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from Ikebukuro StationHours:11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m. / Special exhibitions close: 6:30 p.m.)Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.Admission fee:FreeWebsite:https://animetokyo.jp/en/SNS：X｜https://x.com/animetokyo_info (@animetokyo_info)Instagram｜https://www.instagram.com/animetokyostation/(@animetokyostation)YouTube｜https://www.youtube.com/channel/@AnimeTokyoStationInquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp Press release: https://www.acnnewswire.com/docs/doc/20260209.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

All-new Versa VanTOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that Mitsubishi Motors Philippines Corporation (MMPC), a subsidiary of Mitsubishi Motors in the Philippines, began sales of the all-new Versa Van on February 6. The model is an OEM-supplied commercial vehicle by Nissan Motor Co., Ltd. (hereafter, Nissan).The all-new Versa Van offers five-row seating for up to 15 passengers and features a spacious interior optimized for transporting people, supporting a wide range of commercial applications, including shuttle services. Powered by a 2.5-liter inline four-cylinder diesel engine, the model delivers strong torque from the moment of acceleration, ensuring confident performance even when carrying many passengers or driving on steep inclines. With this new model, Mitsubishi Motors aims to strengthen its commercial vehicle lineup in the Philippines and meet customer needs alongside the existing L300 model.As Alliance partners, Mitsubishi Motors and Nissan are pursuing global collaboration in areas such as joint development and production of next-generation pickup trucks, as well as joining forces to drive business expansion in electrified vehicles. The OEM supply of the all-new Versa Van by Nissan for the Philippine market represents a tangible outcome of this collaboration. Mitsubishi Motors has also begun supplying Nissan with the Rogue Plug-in Hybrid for North America and the Navara for Oceania and has been supplying the Livina to the Philippine market since 2022 — an initiative that improves plant utilization and complements model lineups, building a mutually beneficial partnership. Furthermore, Mitsubishi Motors will receive OEM supply of an all-new EV model derived from Nissan’s new LEAF in 2026 and will introduce the model to the North American market in the latter half of the year.Mitsubishi Motors will continue to leverage diverse partnerships to expand its product lineup, strengthen regional operations, and accelerate initiatives that enhance profitability.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society.For more information on Mitsubishi Motors, please visit the company's website at https://www.mitsubishi-motors.com/en/ Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Sony Corporation (Sony), Mitsubishi Corporation, ADEKA CORPORATION , CHIMEI Corporation, ENEOS Corporation, Formosa Chemicals & Fibre Corporation, Hanwha Impact Corporation, Idemitsu Kosan Co., Ltd., Mitsui Chemicals, Inc., Neste Corporation, Qingdao Haier New Material Development Co., Ltd., SK Geo Centric Co., Ltd., Toray Industries, Inc., and Toray Advanced Materials Korea Inc. have jointly established the world’s first global supply chain consisting of fourteen companies across five countries and regions for the production of renewable plastics*2 that can be used in Sony’s high-performance audio-visual products. The various plastic materials manufactured through this supply chain are slated for use in Sony’s products that will be launched worldwide.＜Overview of the Entire Supply Chain＞(1) Production of renewable naphtha — Neste Corporation / (2) Production of renewable styrene monomer — Idemitsu Kosan Co., Ltd. / (3) Production of renewable polystyrene resin — Formosa Chemicals & Fibre Corporation / (4) Production of renewable para-xylene — SK Geo Centric Co., Ltd. / (5) Production of renewable para-xylene — ENEOS Corporation / (6) Production of renewable terephthalic acid — Hanwha Impact Corporation / (7) Production of renewable PET resin — Toray Advanced Materials Korea Inc. / (8) Production of renewable bisphenol-A — Mitsui Chemicals, Inc. / (9) Production of renewable polycarbonate (PC) resin — CHIMEI Corporation / (10) Production of renewable flame retardants — ADEKA CORPORATION / (11) Production of renewable PC/ABS resin — Qingdao Haier New Material Development Co., Ltd./ (12) Molding manufacturers / (13) Design and manufacturing of finished products — Sony CorporationHigh-performance products such as audio-visual equipment involve a wide variety of plastics, resulting in a complex supply chain that makes it difficult to visualize and manage the entire flow from raw materials. Additionally, plastic components that require high performance in terms of flame resistance and optical properties cannot be fully replaced with plastics produced through material recycling*3, hindering the further reduction of virgin fossil-based plastics in such products.To address these challenges, the fourteen companies collaborated to visualize the existing supply chain for Sony’s products, and created a new supply chain that enables the production of multiple types of renewable plastics from biomass resources with a mass balance approach*4. This allows Sony to proactively source raw materials for its products with the quality and properties equivalent to virgin fossil-based plastics. Defining the supply chain helps the companies track and document GHG (Greenhouse Gas) emissions data over the supply chain in a verifiable way, allowing participating companies to leverage the data to advance efforts to reduce their carbon footprint going forward.This initiative involving wide-ranging partners is part of the ‘Creating NEW from reNEWable materials' project, jointly launched by Sony, which aims to achieve zero usage of virgin fossil-based plastics through the introduction of renewable plastics, and Mitsubishi Corporation.Sony, Mitsubishi Corporation, and the supply chain partners will continue to actively promote the introduction of renewable plastics for high-performance products such as audio-visual products.About ProjectProject Introduction Video：https://youtu.be/3ba3t356sHI[About Sony Corporation]Sony Corporation is a wholly-owned subsidiary of Sony Group Corporation, responsible for the Entertainment, Technology & Services (ET&S) business. With the mission to "create the future of entertainment through the power of technology together with creators", we aim to continue to deliver Kando* to people around the world. Sony is actively promoting initiatives to reduce environmental impact as part of the Sony Group’s "Road to Zero" environmental plan, which aims for zero environmental impact by 2050. In this project, Sony will oversee the entire supply chain and promote the utilization of renewable plastics in our products. https://www.sony.co.jp/en/[About Mitsubishi Corporation]Mitsubishi Corporation (MC) is an integrated trading and investment company that develops and operates businesses across multiple industries together with its global network. MC has eight Business Groups that operate across virtually every industry: Environmental Energy, Materials Solution, Mineral Resources, Urban Development & Infrastructure, Mobility, Food Industry, Smart-Life Creation, and Power Solution. Through these eight Business Groups, MC’s activities have expanded far beyond its traditional trading operations to include project development, production, and manufacturing operations, working in collaboration with our trusted partners around the world. In this project, MC plays a comprehensive role in overseeing the supply chain, including credit delivery management, and promoting the introduction of renewable plastics into Sony products. https://www.mitsubishicorp.com/jp/en/[About ADEKA CORPORATION]ADEKA CORPORATION is a manufacturer of valuable materials with over 100 years of history. ADEKA aims to realize a sustainable society by globally expanding valuable materials that enrich people's lives, such as polymer additives that enhance plastic functionality, advanced semiconductor materials, environmental materials, food products, and agrochemicals. In this project, we manufacture flame retardants with biomass characteristics assigned using a mass balance approach. https://www.adeka.co.jp/en/[About CHIMEI Corporation]CHIMEI is a leading high-performance materials company that designs and manufactures advanced polymer materials, synthetic rubbers, and specialty chemicals, delivering innovative and sustainable solutions for industries worldwide. With a commitment to circularity, environmental responsibility, and close client collaboration, CHIMEI supports and partners with global companies to elevate product performance while jointly minimizing environmental impact. In this project, CHIMEI produces polycarbonate resin (PC) with assigned biomass characteristics using a mass balance approach. https://www.chimeicorp.com/en-US[About ENEOS Corporation]At ENEOS Corporation, our network has grown to about 12,000 ENEOS branded service stations across Japan. ENEOS is expanding business to accommodate energy transitions into sources like hydrogen and Synthetic Fuels in addition to petroleum and petrochemical products produced and manufactured at refineries and factories at various locations in Japan. The ENEOS Group aims to achieve both a stable supply of energy and materials and the realization of a carbon-neutral society, based on its commitment of “Supporting ‘today’s normal,’ taking the lead for ‘tomorrow’s normal.’” In this project, ENEOS manufactures paraxylene (PX) with assigned biomass characteristics using a mass balance approach. https://www.hd.eneos.co.jp/english/[About Formosa Chemicals & Fibre Corporation (FCFC)]FCFC is a comprehensive chemical company that manufactures petrochemical products, synthetic fibers, and plastics. FCFC implements a circular economy to achieve both environmental protection and industrial development, working on the development of green chemicals and the expansion of reusable materials. In this project, FCFC manufactures polystyrene (PS) with assigned biomass characteristics using a mass balance approach. https://www.fcfc.com.tw/[About Hanwha Impact Corporation]Hanwha Impact is a leading petrochemical and investment company, engaged in chemical products and next-generation energy solutions. Hanwha Impact aims to achieve a sustainable society through developing eco-friendly energy solutions and fostering future innovative technologies. In this project, Hanwha Impact produces high-purity terephthalic acid (PTA) with assigned biomass characteristics using a mass balance approach. https://www.hanwhaimpact.com/[About Idemitsu Kosan Co., Ltd.]The Idemitsu Group is engaged in the development, manufacture, and sales of a wide variety areas of Petroleum, Basic Chemicals, High-Performance Materials, Power/Renewable Energy, and in a variety of fields. Idemitsu Kosan is taking on the challenge of an energy transition to help realize a carbon-neutral and circular society by 2050. In the Basic Chemicals business, we are promoting the use of biomass feedstocks and advancing chemical recycling initiatives. In this project, Idemitsu Kosan produces styrene monomer (SM) using a mass balance approach. https://www.idemitsu.com/en/index.html[About Mitsui Chemicals, Inc.]Mitsui Chemicals is a chemical manufacturer that provides solutions for achieving a sustainable society, offering a wide range of products and services from basic chemicals to high-performance materials. Aiming for carbon neutrality by 2050, the company is working to reduce GHG emissions (Scope 1 and 2) and to maximize its contribution to GHG reductions throughout the entire product life cycle. In this project, Mitsui Chemicals produce biomass-derived bisphenol A (BPA) using the mass balance approach. https://jp.mitsuichemicals.com/en/index.htm[About Neste Corporation]Neste (NESTE, Nasdaq Helsinki) creates solutions for mitigating climate change and accelerating a shift to a circular economy. The company is the world’s leading producer of sustainable aviation fuel (SAF), renewable diesel, and renewable and circular solutions for the chemical and plastics industries. In this project, NESTE supplies renewable naphtha made from waste cooking oil and other renewable raw materials. https://www.neste.com/[About Qingdao Haier New Material Development Co., Ltd.]Haier is a global home appliance manufacturer originating, offering a wide range of products including refrigerators and washing machines. Haier New Materials, a subsidiary of the Haier Group, reduces carbon emissions and promotes the construction of a sustainable society by recycling regenerated plastic materials from disassembled home appliances. In this project, Haier produces recycled PC/ABS blended with a flame retardant with assigned biomass characteristics. https://www.haierdawn-plastics.com/[About SK Geo Centric Co., Ltd.]SKGC is a leading chemical company, offering petrochemical products such as olefins, aromatics and polymers. SKGC is upgrading our portfolio to provide more sustainable products in consumer’s daily lives. In this project, SKGC manufactures paraxylene (PX) with assigned biomass characteristics using a mass balance approach. https://www.skgeocentric.com/[About Toray Industries, Inc.]Toray Industries, Inc., is a global leader in advanced materials innovation, comprising more than 300 affiliated companies and approximately 48,000 employees worldwide. Since 1926, Toray Industries have continuously expanded our business portfolio—from Fibers & Textiles, to Resins & Chemicals, Films, Electronics & Information Materials, Carbon Fiber Composite Materials, Pharmaceuticals & Medical Products, as well as Water Treatment & Environment. April 2026 marks the 100th anniversary of Toray’s founding. In line with our Corporate Philosophy, “Contributing to society through the creation of new value with innovative ideas, technologies and products,” we will commit to delivering fundamental solutions to global-scale challenges. https://www.toray.com/ [About Toray Advanced Materials Korea Inc.]TAK is a comprehensive chemical manufacturer, offering various products from daily life to high-end industries. With consistent investing and innovation, TAK provides material solutions for climate crisis. In this project, TAK manufactures PET resin and film with assigned biomass characteristics using a mass balance approach. https://www.torayamk.com *1 In the manufacturing of audio-visual products, this initiative is regarded as a “world’s first” in that it visualizes the entire supply chain from raw materials to finished products and converts raw materials to biomass-based materials at mass-production scale.(Based on research conducted by Mitsubishi Corporation. At the time of announcement in Feb. 2026)*2 Plastics made from renewable biomass resources instead of fossil resources.*3 A method of reusing plastic materials by returning used plastics to their original form through physical processes such as crushing, cleaning, and melting, rather than discarding them.*4 This is a method of allocating the characteristics of specific raw materials, such as biomass resources, to a portion of the product based on the input amount of those materials when they are mixed with non-specific raw materials during the distribution and processing stages from raw materials to products.* "Sony", "SONY" logo and any other product names, service names or logo marks used in this press release are registered trademarks or trademarks of Sony Group Corporation or its affiliates. Other product names, service names, company names or logo marks are trademarked and copyrighted properties of their respective owners and/or licensors.* Visual content in this release may be removed without prior notice due to licensing or copyright reasons.* Kando is a Japanese word that roughly translates to the sense of awe and emotion you feel when experiencing something beautiful and amazing for the first time.MaterialityBased on the Three Corporate Principles, which serve as MC’s core philosophy, MC has continued to grow together with society by contributing to the sustainable development of society through its business activities while pursuing value creation. While continuously creating Shared Value guided by the Materiality, a set of crucial societal issues, MC will continue to strengthen its efforts towards sustainable corporate growth. Guided by this Materiality, MC will continue to strengthen its efforts towards sustainable corporate growth. Out of the six material issues relating to “Realizing a Carbon Neutral Society and Striving to Enrich Society Both Materially and Spiritually”, this project’s activities particularly support “Contributing to Decarbonized Societies” and “Promoting Stable, Sustainable Societies and Lifestyles.”Inquiry RecipientMitsubishi CorporationTelephone:+81-3-3210-2171 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and SHANGHAI, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, “Henlius”) announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan.Serplulimab, a novel anti-PD-1 monoclonal antibody developed by Henlius, is reported to possess a unique binding mode that differs from existing anti-PD-1 antibodies. 1 In China, it has been approved for indications such as squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsNSCLC), and esophageal squamous cell carcinoma (ESCC). In the EU, it has been approved for ES-SCLC. It is the world's first anti-PD-1 antibody to be used as a first-line treatment for ES-SCLC.In Japan, Henlius is currently conducting a Phase II bridging clinical trial for ES-SCLC, and plans to submit an application for fiscal year 2026 based on the results of this trial as well as the Phase III clinical trial data that supported approvals for this indication in China and Europe. Furthermore, a Phase III multi-national clinical trial for non-high-frequency microsatellite instability (non-MSI-High) metastatic colorectal cancer is underway, with development for new indications also planned.In Japan, it is estimated that there are approximately 13,000 patients diagnosed with ES-SCLC and about 28,000 patients diagnosed with non-MSI-High metastatic colorectal cancer, both of which are considered to have high unmet medical needs. 2,3,4,5Under the terms of this agreement, Eisai will obtain exclusive rights to commercialize serplulimab in Japan. In addition to ES-SCLC and non-MSI-High metastatic colorectal cancer, Henlius plans to also conduct a clinical trial for perioperative gastric cancer in Japan, and will assume the responsibilities of the Marketing Authorization Holder.Eisai will pay Henlius a contractual upfront payment of USD 75 million (approximately JPY 11.6 billion*), in addition to regulatory milestone payments of up to USD 80.01 million (approximately JPY 12.4 billion), and sales milestone payments of up to USD 233.3 million (approximately JPY 36.2 billion). Furthermore, Eisai will pay double-digit royalties based on sales of the product. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2026.“We are pleased to collaborate with Eisai in Japan to advance the development of serplulimab in this important market,” said Dr. Jason Zhu, CEO of Henlius. “Serplulimab has demonstrated its potential across multiple tumor types through global clinical development and regulatory approvals, and Japan represents a critical step in its international journey. By combining Henlius’ innovation capabilities with Eisai’s deep local expertise, we aim to support the efficient development of serplulimab and address unmet medical needs for patients in Japan.”“Serplulimab is an anti-PD-1 monoclonal antibody that has been developed with high priority for indications with significant unmet medical needs, including ES-SCLC, and has already obtained approval for multiple indications in China and the EU. We anticipate that it will also become a promising treatment option in Japan for ES-SCLC and non-MSI-high metastatic colorectal cancer, for which development is underway, as well as for other intractable cancers,” said Toshihiko Yusa, Executive Officer and Head of Japan Business at Eisai. “Eisai will make every effort, in cooperation with Henlius, to deliver serplulimab to patients as soon as possible.”* Converted at an exchange rate of USD 1 = JPY 155MEDIA CONTACTSEisai Co., Ltd. Public Relations DepartmentTEL: +81 (0)3-3817-5120Shanghai Henlius Biotech Inc.Janice Hanjiayi_han@henlius.comBella Zhouwenting_zhou@henlius.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Shanghai Henlius Biotech Inc.Venus Hu junyan_Hu@henlius.com About SerplulimabSerplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) is an anti-PD-1 monoclonal antibody first developed by Shanghai Henlius Biotech, Inc. (“Henlius”), and launched in China in 2022. It has been approved by the National Medical Products Administration of China for indications including squamous non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma, and non-squamous non-small cell lung cancer, and is the world's first anti-PD-1 antibody to be used as a first-line treatment for ESSCLC. It has been approved for the treatment of ES-SCLC in over 40 markets, including the EU, Southeast Asia (Indonesia, Cambodia, Thailand, Singapore, Malaysia), and South America (Peru). Henlius is actively promoting the broader use of serplulimab both as a standalone product and in combination with other innovative therapies, including those developed in-house and externally. Furthermore, the company is conducting numerous clinical trials worldwide on therapies for conditions where existing anti-PD-1 antibodies have not yet been used, focusing on indications such as lung cancer and gastrointestinal tumors.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Shanghai Henlius Biotech, Inc.Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across 60 countries and regions worldwide, including seven approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and four products authorized by the European Medicines Agency (EMA), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.References1. Issafras H, Fan S, Tseng C-L, Cheng Y, Lin P, Xiao L, et al. (2021) Structural basis of HLX10 PD1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. PLoS ONE 16(12): e0257972. https://doi.org/10.1371/journal.pone.02579722. National Cancer Center Japan, Cancer Information Service, Cancer Statistics (Japanese only) https://ganjoho.jp/reg_stat/statistics/stat/cancer/index.html Last accessed: January 2026.3. Sabari, J., Lok, B., Laird, J. et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 14, 549–561 (2017).4. Fujiyoshi K, Yamamoto G, Takenoya T et al. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. Anticancer Res. 2017;37(1):239- 247.5. Cancer Statistics in Japan-2025 https://www.fpcr.or.jp/pdf/pamphlet/cancer_statistics_2025.pdf (P30) Last accessed: January 2026. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Kawasaki and Tokyo, Japan, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Japan Limited and JMDC Inc. today announced the commencement of a collaboration aimed at advancing medical care and contributing to the establishment of a sustainable healthcare system in Japan.This collaboration, which began on January 5, leverages JMDC's expertise in utilizing anonymized medical data and Fujitsu Japan's customer base. Fujitsu Japan holds the top share in the Japanese electronic health record (EHR) market for medical institutions. This synergy will accelerate the utilization of medical data by medical institutions and organizations that are part of the healthcare system, while also supporting data-driven management decision-making.This collaboration will see the two companies combine Fujitsu Japan's knowledge in the medical field and advanced technologies including AI, with JMDC's prediction models based on insurance user data and its expertise cultivated through Pep Up, one of Japan's largest personal health record services used by 7.7 million people. This will expand the scope of data utilization from DPC data [1] to comprehensive EHR data. This initiative will further promote the utilization of medical data, contributing to improved management for medical institutions and advanced research for pharmaceutical companies, government agencies, and academia.Going forward, Fujitsu Japan will contribute to the realization of digital hospitals that promote DX in medical institutions, while JMDC will advance initiatives that contribute to "building a sustainable healthcare system through addressing social issues with the power of data and ICT" and "accelerating the societal integration of data."Overview of the collaborationFujitsu Japan will provide Dashboard 360, a solution that enables visualization and analysis of management and clinical data, free of charge [2] to medical institutions that agree to provide anonymized DPC data [3]. Dashboard 360 is offered as part of Fujitsu Limited's Uvance business model, which addresses societal challenges, specifically within the Smart Hospital offering that maximizes hospital operational efficiency and effectiveness. It is a component of the Healthcare Management Platform, a suite of services designed to optimize patient flow [4] in acute care hospitals and support the resolution of management challenges.Dashboard 360 seamlessly integrates with EHRs, allowing for factor analysis of issues such as declining bed occupancy rates and waiting times for hospitalization or surgery, based on information including inpatient care and outpatient conditions leading to hospitalization. It also features a benchmarking function, utilizing data provided by JMDC and DPC data from medical institutions, to support timely decision-making in hospital management.JMDC will collaborate with Fujitsu Japan to anonymize DPC data in a secure environment and provide it to pharmaceutical companies, government agencies, and universities for research purposes. Additionally, by combining this with JMDC's accumulated insurance user data, covering approximately 20 million individuals, the collaboration will visualize the entire patient journey from pre-onset abnormal test results to inpatient treatment and post-discharge prognosis. This will enable early detection of diseases through screening of potential patients, prevention of severe cases by identifying risk factors, and precise evaluation of long-term treatment effects and drug safety in real-world settings, thereby contributing to the improvement of medical quality and efficiency.Figure: Collaboration overviewBackgroundIn Japan, the aging population and increasing medical expenses are pressing concerns. Challenges such as a shortage of healthcare professionals and financial difficulties for medical institutions persist. By leveraging medical data, it is expected that these challenges can be addressed through improved diagnostic accuracy, enhanced operational efficiency, development of new treatment methods, and strengthened regional healthcare collaboration.[1] DPC data:Data used to calculate medical costs based on the patient's diagnosis and treatment content during hospitalization. It includes patient information, diagnoses, surgical procedures, medications used, and is expected to be utilized for analyzing medical quality and hospital management, as well as for formulating healthcare policies.[2] Agreement to provide anonymized DPC data:Fujitsu Japan is entrusted by medical institutions with the creation of anonymized information such as DPC data, and the medical institutions grant Fujitsu Japan permission for secondary use of the created anonymized information.[3] Free of charge:No initial setup or usage fees. A separate license fee for the BI tool included in the service is required.[4] Patient flow:The management of the entire patient process from hospital visit to discharge.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout JMDCEstablished in 2002 as a pioneer in the medical big data industry, JMDC possesses proprietary anonymization processing technology and data analysis/aggregation technology. Based on the analysis of over 1.573 billion medical claims data and over 76 million health checkup data (as of March 2025), JMDC provide information services, including support for health promotion programs for payers, drug safety evaluation, and healthcare economics analysis. JMDC is committed to realizing a healthy society through medical data and analytical capabilities, providing a single index for health (Health Age) and web services for health promotion (Pep Up), among others. Find out more: https://www.jmdc.co.jp/en/Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesJMDC Inc.JMDC Inc. IR OfficeEmail: jmdc-pr@jmdc.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Tokyo and Kawasaki, Japan, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Genesys® Cloud Services, Inc. (Headquarters: Minato-ku, Tokyo; President: Paul Ito Ricci, hereinafter Genesys), a global cloud leader in AI-Powered Experience Orchestration, and Fujitsu Limited (Headquarters: Kawasaki City, Kanagawa Prefecture; President and CEO: Takahito Tokita; hereinafter Fujitsu) which led the implementation of Genesys Cloud, announced the successful transformation of AEON Financial Service Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President and CEO: Tomoharu Fukayama; hereinafter AEON Financial Service) contact center operations and the completion of its effectiveness evaluation.As part of this contact center transformation initiative, AEON Financial Service deployed Genesys Cloud™, a unified experience orchestration platform. Because of the composability of the Genesys Cloud platform, Fujitsu implemented customizations to meet its unique business requirements, including reporting management and system integrations, and will continue to support maintenance and operations. With over 2,500 seats, this deployment is among the largest of its kind in Japan’s financial sector.AEON Financial Service plans to introduce an “AI Concierge (Voice Bot)” utilizing speech recognition technology. This will allow customers to be guided to the appropriate menu through natural spoken dialogue, eliminating the need for phone keypad input. Furthermore, AEON Financial Service is considering expanding the solution to other contact centers across the AEON Group. Genesys and Fujitsu will continue to support the advancement of contact center systems across the entire AEON Group.Paul Ito Ricci, President of Genesys Japan, commented:"AEON Financial Service is demonstrating how modern experience orchestration can transform customer engagement at scale in a short period.By moving its contact center platform to the cloud, the company has been able to internalize system development and significantly accelerate the speed at which it can deliver more convenient services to address customers’ needs. . We are committed to supporting AEON Financial Service through Genesys Cloud as they utilize AI to deliver innovative, personalized and empathic customer experiences and seamless support for each individual at scale."Masaru Yagi, Executive Vice President, Fujitsu Limited, commented:"We are pleased to announce the successful introduction of Genesys Cloud to enhance the contact center operations for AEON Financial Service. This initiative addresses the crucial and growing need for contact center transformation in recent years. We are confident that this project meaningfully contributes to establishing an operator-first environment where high-quality customer experience can be delivered without added burden. Fujitsu will continue to support the implementation and operation of Genesys Cloud as a solution vendor, leveraging AI and other technologies to support AEON Financial Group and many other companies."BackgroundAEON Financial Service call center is responsible for comprehensive support across a wide array of financial services, including banking, insurance, and loans, in addition to payment services such as AEON Pay, AEON Card, and WAON. A significant challenge for the company was the increase in customer waiting times due to the growing variety of inquiry types and the increasing specialization and segmentation of internal guidance points. Moreover, the conventional on-premises call center system required modernization to effectively support future service expansion.Improvements driven by the contact center operations overhaulFollowing the deployment of Genesys Cloud and the overhaul of its contact center operations, AEON Financial Service has realized the following benefits within the first six months:1. Higher self-service completion ratesBy expanding self-service options within the IVR (Interactive Voice Response) system, the self-completion rate for the menu option that allows customers to report payments after a failed withdrawal improved by 21 percentage points compared to the previous system, helping reduce customer wait times.2. Automated SMS supportBy implementing a mechanism that automatically sends an SMS in response to IVR inquiries, simple questions can now be resolved through self-service. This allows operators to concentrate on more complex tasks.3. Rapid feature enhancements and flexible operationsThe use of a cloud service with the requirement of a low-code functionality enables the speedy deployment of new services and quick changes to the IVR structure. Furthermore, future efforts to bring development in-house will allow for even faster response times.About GenesysGenesys® empowers more than 8,000 organizations worldwide to create the best customer and employee experiences. With agentic AI at its core, Genesys Cloud™ is the AI-Powered Experience Orchestration platform that connects people, systems, data and AI across the enterprise. As a result, organizations can drive customer loyalty, growth and retention while increasing operational efficiency and teamwork across human and AI workforces. www.genesys.com/ja-jpAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesGenesys Cloud Services, Inc. Genesys PR Office (Initial Inc.)Contacts: Hirabayashi, Nagaoka, AkiyamaTel: +81-3-5572-7334 Email: genesys_pr@vectorinc.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 5, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, announced today that it has established a total solution system capable of supporting all processes in the contract manufacturing business for various test kits including in vitro diagnostics.Until now, TANAKA has been responsible primarily for processes from developing and manufacturing test kits to bulk production of extraction buffer. At this time, TANAKA established dedicated production lines for the dispensing and packaging of extraction buffer, creating a system that enables it to complete all processes in-house from development to manufacture of final products. This enables TANAKA to reduce costs and the time for external outsourcing and transportation, making it possible to deliver high-quality products in shorter times.In addition, TANAKA will seek to expand production capacity and shorten lead times even further by introducing additional state-of-the-art automatic assembly lines and extract dispensing equipment with a target of March 2026.TANAKA's Total Solution SystemFlexible responses achieved through reinforced integrated production systemBy establishing this total solution system, TANAKA will be able to provide comprehensive contract services covering all processes from test kit development and manufacturing to bulk production, dispensing, and packaging of extraction buffer. This will enable TANAKA to continuously support customers from the development stage through mass production while also accommodating request for individual processes such as extraction buffer dispensing only.By bringing production processes entirely in-house, TANAKA will further reinforce stable supply and quality control.A track record in the development of diagnostic test kits across a wide range of disease areas and examples of deploymentTANAKA offers in vitro diagnostics for a wide range of infectious diseases including respiratory tract infections, such as influenza and COVID-19, as well as dengue and ZIKA viruses. These test kits are compatible with various sample types such as saliva, blood, and urine, and support rapid and accurate testing in clinical settings.Respiratory Tract InfectionsMosquito-Born Infectious DiseasesObstetrics・ Influenza virus・ Adenovirus・ RS virus・ Human meta-virus・ COVID-19・Group A beta hemolytic Streptococcus (Streptococcus pyogenes)・ Dengue virus・ Zika virus・ Chikungunya virus・ Pregnancy testingExamples of Disease Areas That TANAKA Deploys Tests ForTechnical foundations and future outlookTANAKA started research and development of in vitro diagnostics around 2006 and has accumulated technologies centered on nano-colloidal gold (Au). It possesses a diverse range of technologies that support the enhancement of reagent performance using immunochromatographic assay, including protein immobilization technology, non-specific absorption expression technology, and antigen-antibody reaction enhancement technology, TANAKA provides contract manufacturing of high-quality test kits that leverage these technologies in accordance with the ISO 13485 system.Going forward, TANAKA will leverage this total solution system to develop new diagnostics in collaboration with partner companies, while contributing to solutions to social issues and advancement of the field of medicine.About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ended December 2024 were 846.9 billion yen.TANAKA Industrial Precious Metal Materials Portalhttps://tanaka-preciousmetals.comProduct inquiriesTANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-on-industrial-products/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/Press release: https://www.acnnewswire.com/docs/files/20260205_EN.pdf Disclaimer:ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE. NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

- A branding area showcasing Hitachi’s journey from its founding to the vision it aims to achieve through Inspire 2027.(Top left)- A three-sided immersive theater presenting the future of buildings through powerful, engaging visual experiences.(Top right)- The entrance to the exhibition area where visitors can experience Hitachi’s comprehensive capabilities broughttogether under the One Hitachi. (Bottom left)- An interactive corner that visualizes and demonstrates commercial air conditioning control using augmented realitytechnology. (Bottom right)TOKYO, Feb 5, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and Hitachi Building Systems Co., Ltd. (“Hitachi Building Systems”, part of Hitachi’s Connective Industries Sector (“CI Sector”)) will significantly expand the exhibits at “Hitachi Building Solutions Lab”, a customer co-creation research facility. The facility, located in Tokyo, will reopen in its new form on March 2, 2026. The exhibition is being expanded to accelerate digital innovation in the field of buildings, which are bases for people's activities, with a view toward the realization of a harmonized society where the environment, wellbeing and economic growth coexist in harmony as envisioned in the Inspire 2027, Hitachi Group's new management plan. To address social issues, including the decline in the working population and carbon neutrality, the new exhibition will use AI, digital twin, and augmented reality (AR) technologies to propose the latest solutions addressed by One Hitachi, including HMAX for Buildings: BuilMirai, a suite of next-generation solutions that combine domain knowledge and advanced AI.In the future, Hitachi and Hitachi Building Systems will advance collaborative creation with developers, design offices, construction companies, owners of buildings, building management companies and other customers, as well as with partners at the Hitachi Building Solutions Lab.Outline of the new exhibition1. Building management using physical AI realized using digital twin technologiesTo address the labor shortage in building management operations, the new exhibition will propose a future vision for building management in a demonstration that combines AI and digital twin solutions, based on the latest technologies being developed by Hitachi's Research & Development Group. Visitors will be able to experience a digital twin solution for the operation of a guide robot in a physical space after they view optimal solutions proposed by an AI agent based on the results of people flow analyses and provide instructions to the robot in a virtual space.2. Air conditioning and demand control solution to accelerate GX and ZEB*1The exhibition will propose solutions for decarbonizing and reducing energy expenses of buildings with a view toward the achievement of carbon neutrality in 2050. The Hitachi Building Solutions Lab will provide an experience-based exhibition that visualizes the exiida air conditioning IoT solution from Hitachi Global Life Solutions, Inc. (“Hitachi GLS”, part of Hitachi’s CI Sector) and controls an actual business-use air conditioning system using AR technologies.*1 GX: Green Transformation ZEB: Net Zero Energy Building3. Seeking seamless movement within buildings and wellbeingThe exhibition will propose experiences that facilitate seamless movement using integrated elevators and other building equipment with a view toward supporting people's diverse workstyles and increasing the safety and quality of life (QoL) of building users. It will enable visitors to experience the link between the connected features of Hitachi's standard elevator set to be released in April 2026 and mobile robots, connections with the Hybrid-PCS vehicle-to-everything (V2X) system*2 capable of supplying power to elevators and other building equipment by connecting to electric vehicles during a power outage, and the latest security system using an Apple Wallet authentication system*3 .*2 V2X: Vehicle to Everything (Technology enabling electric vehicles, residential houses, buildings and the power grid, etc. to supply power to each other by connecting vehicles to various devices and infrastructure.)*3 Contactless authentication system using smartphones. In this system, users' identification documents and driver's licenses are registered in the Apple Wallet application so that the user's identity and age can be verified in real time using Face ID, Touch ID or NFC.4. Strengthening comprehensive solution capabilities such as One Hitachi To address increasingly diverse and complicated social issues and mission-critical areas, the exhibition will showcase examples of the Hitachi Group's solutions in its broad range of business sectors centered on HMAX for Buildings and products in the CI Sector. They will include AI safety solutions*4 to facilitate increased work efficiency and improved safety for frontline engineers, Hitachi Industrial Equipment Systems Co., Ltd.'s generative AI agent for the provision of dialogue-based information on the operation and maintenance of industrial equipment, and Hitachi GLS' connected home appliances. This will strengthen Hitachi's comprehensive ability to propose solutions as One Hitachi.*4 News released on November 14, 2025: Hitachi Commences the On-Site Application of an AI-Based Safety Solution for Engineers in the Field — Dangerous Location Notification https://www.hitachi.com/New/cnews/month/2025/11/251114a.htmlOutline of the Hitachi Building Solutions Lab Address : 4-16-29 Nakagawa, Adachi-ku, TokyoDate of opening : April 2, 2023Closed on : Saturdays, Sundays, national holidays and Hitachi's non-business daysOperating hours : 10:00 a.m. to 5:00 p.m.Tour style : Fully attended tours by reservation only (In principle, tours are open only to developers, design offices, constructors, owners of buildings, management associations and other customers and partners.)Hitachi’s CI Sector focuses on “Integrated Industry Automation,” which aims to expand “HMAX Industry” into growth industries horizontally. HMAX Industry provides next-generation solutions for industry field that combine data from an abundant installed base of products (digitalized assets), domain knowledge, and advanced AI. As part of the CI Sector, Hitachi Building Systems aims to drive innovation for frontline engineers and contribute to improving people's wellbeing through the delivery of HMAX for Buildings: BuilMirai that embodies Lumada 3.0.An exhibit introducing AI safety solution for frontline engineers and Hitachi’s smart building services through digitalsignage, highlighting on-site transformation powered by AI.Trademark Notice: All trademarks and product names are the property of their respective owners.Hitachi Building Systems Websitehttps://www.hbs.co.jp/Hitachi Global Websitehttps://www.hitachi.com/businesses/elevator/About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, February 3,2026 - (JCN Newswire via SeaPRwire.com) - Japantastics, Inc, a Tokyo-based company dedicated to promoting and distributing authentic Japan-made products to a global audience, has announced the official launch of Japantastics.jp, an online commerce platform that discovers and promotes unique, high-quality Japan-made products - focusing on craftsmanship, engineering, and stories that have long remained hidden beyond Japan's borders.Japan is home to a remarkable depth of artisanal skill and manufacturing excellence. Yet while global interest in Japan continues to rise — reflected in 40+ million visitors in 2025 — many highly skilled artisans and small manufacturers remain oriented entirely toward the domestic market. As a result, much of Japan’s finest craftsmanship remains difficult to encounter outside the country.Japantastics was founded to fill this divide, and curate products based on craft integrity, technical excellence, and cultural context, introducing makers whose work reflects years—often decades—of dedication and refinement. Rather than functioning as a conventional e-commerce marketplace, the Japantastics platform serves to discover and illuminate unique Japan-made crafts and products and will continue to broaden its lineup by discovering and introducing exceptional, lesser-known items from across the country.“Interest in premium Japanese products abroad continues to expand,” said Aki Tsukioka, Co-founder of Japantastics, Inc. "However, many artisans lack the resources, language support, and international channels needed to reach customers overseas. Japantastics exists to bridge that gap—not by simply selling products, but by communicating the value systems, techniques, and stories behind them."At the core of Japantastics is a belief that truly meaningful products are not disposable commodities, but lifelong tools shaped by human intention. By working closely with artisans and manufacturers, the company aims to present Japan-made goods not as trends, but as enduring objects that reward long-term use and appreciation. Each product is introduced with its background, production philosophy, and practical relevance for modern life.The Japantastics platform will continue to expand its lineup by discovering lesser-known makers across Japan - ranging from traditional crafts to contemporary manufacturing - while maintaining a highly selective, story-driven approach to curation. With this model, Japantastics positions itself as a cultural bridge: connecting Japanese creators with global audiences who value authenticity, quality, and depth over mass production.About JapantasticsJapantastics, Inc. is a Tokyo-based company dedicated to introducing authentic Japan-made products to global audiences. Through careful curation and storytelling, the company connects Japanese artisans and small manufacturers with customers worldwide who seek products defined by craftsmanship, longevity, and cultural meaning. Visit Japantastics.jp.Media Contact: Japantastics, Inc. Email: japantastics@gmail.com Website: https://japantastics.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

KYOTO, Japan, Feb. 4, 2026 - (JCN Newswire via SeaPRwire.com) - Valuufy, a Kyoto-based stakeholder impact intelligence company, today released a whitepaper analyzing the nine Nikkei 225 automakers,* and six international benchmarks,** across 168 validated performance metrics, with comparative benchmarking. The findings reveal a 55-point gap between policy commitment and verification performance, reflecting the industry-wide challenge of building measurement infrastructure to match ambitious commitments.Japanese automakers are major competitors in global markets and represent significant holdings in international portfolios. For investors evaluating automotive holdings, this gap creates material uncertainty, but also an opportunity for those who can identify which companies back their commitments with measurable outcomes.[Fig.1: Impact Research Paper - Executive Summary Page].Despite policy commitments averaging 77% across all ValuuCompass impact topics, only 22% translate to quantified outcomes, and just 10% receive third-party verification. This creates potential risk for investors relying on unverified disclosure data, and reflects the industry-wide challenge of building measurement infrastructure to match ambitious commitments.The Measurement Gap"The 55-point policy-performance gap represents fundamental infrastructure deficiencies in translating policy into measurable action," said Kyle Barnes, CEO of Valuufy. "Companies with unsubstantiated claims face potential regulatory scrutiny and reputational damage as verification standards tighten under emerging regulations, including the EU's CSRD and Japan's SSBJ."Value Washing: Beyond Greenwashing"Value washing occurs when companies make stakeholder commitments exceeding actual delivery," said Dr Philip Sugai, Director of Research at Valuufy. "Unlike greenwashing, which focuses on environmental claims, value washing extends across all seven stakeholder groups, including the company, its employees, customers, partners, society, nature and shareholders. The opposite is Value Hushing: when companies achieve strong results but fail to disclose them due to measurement infrastructure gaps."The assessment identified critical measurement blind spots in channel partners, where most environmental and human rights impacts concentrate, and society, including community relationships essential for operational continuity. Only 34% of channel partner metrics have calculation-ready disclosures, while 12% of industry disclosures are claims without quantitative support.Verification Patterns: Japan and International ComparisonJapanese automakers demonstrate comprehensive policy commitments but lower third-party verification rates, averaging 5% compared to 18% for the international peers assessed. This pattern may reflect corporate governance approaches that emphasize internal control over external validation.Among international manufacturers included in the benchmarking, Volkswagen leads with a verification rate of 34%, followed by Hyundai at 26% and BYD at 23%.[Fig.2: Impact Report - Auto Sector Rankings Page]."Building proper measurement infrastructure takes 3-5 years," Barnes added. "Companies starting now can achieve operational maturity by 2028-2029, positioning themselves to meet emerging regulatory requirements across jurisdictions."This Japan automotive analysis is the first in a series of industry reports using ValuuCompass methodology. Valuufy will publish sector-specific assessments throughout 2026. Expanded coverage of international automotive markets is available on demand for investors and companies seeking broader benchmarking.*Nikkei 225 Automakers: Toyota, Honda, Nissan, Suzuki, Mazda, Subaru, Mitsubishi Motors, Isuzu, Hino Motors.**International Automakers: Volkswagen, Hyundai, BYD, Ford, Tesla, General Motors.Download the whitepaper: www.valuufy.com/automotive-analysis Media Contact: Marco Koeder, Chief Operating Officer, Valuufy. E: marco@valuufy.comRequest a briefing or pilot assessment: learnmore@valuufy.comAbout ValuuCompassValuuCompass(TM) is the stakeholder intelligence platform used in this analysis. Built on over a decade of academic research at Doshisha University's Value Research Center, it measures performance across seven stakeholder dimensions using 168 validated metrics. Unlike traditional black-box ESG ratings, ValuuCompass delivers transparent, glass-box measurement where methodology is fully visible. Companies use it to identify measurement gaps and strengthen disclosure infrastructure. Investors use it to benchmark holdings and assess verification maturity. The platform has been validated through Fortune 500 pilot programs and has been featured at the UN Science Summit for the last four years.About ValuufyValuufy is a Kyoto-based stakeholder impact intelligence company founded in 2024, emerging from over a decade of academic research at Doshisha University's Value Research Center. The company delivers impact measurement, competitive benchmarking, and analysis for investors and organizations. Featured for four consecutive years at the UN Science Summit and recognized as a TiE50 Top 50 Global Startup 2025 and Rising Star at Global Startup Expo 2025, Valuufy is guided by an Advisory Council including former leaders from Apple, Cisco Systems, Sustainalytics and S&P Global. https://valuufy.com.[Fig.3: Japan Automobile Manufacturers' Impact Measurement Challenge]DisclaimerThis analysis is based on publicly available information only and does not constitute investment advice, financial guidance, or any form of professional recommendation. Performance metrics reflect the percentage of quantified outcomes reported across 168 indicators (maximum 100%). Data was collected and analyzed between October 2025 and January 2026. Companies may have updated their disclosures after this period. The findings reflect Valuufy's independent assessment methodology and may differ from other analytical frameworks. Mention of specific companies does not constitute endorsement or criticism beyond the factual observations presented. Full disclaimer: www.valuufy.com/disclaimer Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 4, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI, TSE Code: 7011) announced that order intake increased 12.6% year-on-year to ¥5,029.1 billion in the three quarters ended December 31, 2025. Revenue rose 9.2% year-on-year to ¥3,326.9 billion, resulting in profit from business activities (business profit) of ¥301.2 billion, a 25.5% increase over the previous fiscal year, which represented a business profit margin of 9.1%. Profit attributable to owners of parent (net income) was ¥210.9 billion, an increase of 22.6% year-on-year, with a net income margin of 6.3%. EBITDA was ¥393.1 billion, a 21.0% increase over Q1-3 FY2024, with an EBITDA margin of 11.8%.(billion yen, except where otherwise stated)Q1-3 FY2025 Financial ResultsQ1-3 FY2024 (Note)Q1-3 FY2025YoYYoY%Order Intake4,468.15,029.1+561.0+12.6%Revenue3,047.03,326.9+279.9+9.2%Profit from Business ActivitiesProfit Margin240.17.9%301.29.1%+61.1+1.2 pts+25.5%-Profit Attributable to Owners of ParentProfit Margin172.15.6%210.96.3%+38.8+0.7 pts+22.6%-EBITDAEBITDA Margin324.910.7%393.111.8%+68.1+1.1 pts+21.0%-FCF-143.7167.6+311.4-(Note) Q1-3 FY2024 results have been retroactively adjusted to reflect the planned sale of Mitsubishi Logisnext (ML) shares. For more information on the ML sale, please refer to the following press release published on September 30, 2025: ML Sale Announcement(billion yen, except where otherwise stated)Q1-3 FY2025 Financial Results by SegmentOrder IntakeRevenueBusiness ProfitQ1-3FY2025YoY (Note)Q1-3FY2025YoY (Note)Q1-3FY2025YoY (Note)Energy Systems (Energy)2,857.0+889.91,354.7+75.9146.7-7.7Plants & Infrastructure Systems (P&I)891.3+77.7633.9+47.464.9+25.2Logistics, Thermal & Drive Systems (LT&D)444.3-46.6437.0-27.618.4+1.2Aircraft, Defense & Space (ADS)837.0-345.0891.2+201.6105.3+35.6Others, Corporate & Eliminations (OC&E)-0.6-15.09.9-17.4-34.2+6.8Total5,029.1+561.03,326.9+279.9301.2+61.1(Note) Q1-3 FY2024 results on which YoY figures are based have been retroactively adjusted to reflect the planned sale of ML shares.In Energy, order intake increased by ¥889.9 billion YoY mainly due to continued strong demand in Gas Turbine Combined Cycle (GTCC). Contracts for 31 large frame gas turbine units—up 15 units YoY—were concluded during Q1-3, the majority of which were from customers in North America and Asia. Revenue increased by ¥75.9 billion YoY; the largest gains were seen in GTCC, which continued to execute its sizeable backlog. Segment business profit decreased by ¥7.7 billion YoY mainly due to one-time expenses in Steam Power, which offset strong performance in GTCC from higher revenue and improved margins.In P&I, order intake increased by ¥77.7 billion YoY due to the booking of a large project in Engineering. Revenue grew by ¥47.4 billion. Improved margins in Metals Machinery and Machinery Systems helped to raise segment business profit by ¥25.2 billion YoY.In LT&D, revenue decreased by ¥27.6 billion YoY due to a decline in units sold in Turbochargers and Heating, Ventilation & Air Conditioning (HVAC). Steady performance in Engines on the back of strong demand in Asia, combined with the rebound from one-time expenses associated with a supply chain disruption in Turbochargers during the previous fiscal year, resulted in a ¥1.2 billion YoY increase in segment business profit.In ADS, order intake decreased by ¥345.0 billion YoY due to a high base effect from large orders booked in Defense & Space during the previous fiscal year. Revenue increased by ¥201.6 billion YoY, mainly in Defense & Space, where steady progress in backlog execution continued. Increased revenue and higher margins in Defense & Space and Commercial Aviation served to increase segment business profit by ¥35.6 billion YoY.FY2025 Earnings ForecastMHI revised its guidance for the period ending March 31, 2026, increasing the forecasts for order intake, business profit, net income, EBITDA, and FCF over the previous announcement made November 7, 2025, based on stronger-than-anticipated performance through Q3. The full-year dividend forecast of 24 yen per share was unchanged.(billion yen, except where otherwise stated)FY2025 Earnings ForecastFY2024Actual (Note)FY2025Forecast(Previous)FY2025Forecast(Revised)Revised vs.PreviousOrder Intake6,405.16,100.06,700.0+600.0Revenue4,361.14,800.04,800.0-Profit from Business ActivitiesProfit Margin354.98.1%390.08.1%410.08.5%+20.0+0.4 ptsProfit Attributable to Owners of ParentProfit Margin245.45.6%230.04.8%260.05.4%+30.0+0.6 ptsROE10.7%10%10%-EBITDAEBITDA Margin469.910.8%510.010.6%530.011.0%+20.0+0.4 ptsFCF342.70.0200.0+200.0Dividends23 yen24 yen24 yen-(Note) FY2024 results have been retroactively adjusted to reflect the planned sale of ML shares.(billion yen, except where otherwise stated)FY2025 Earnings Forecast by SegmentOrder IntakeRevenueBusiness ProfitPreviousRevisedPreviousRevisedPreviousRevisedEnergy3,200.03,600.02,000.02,000.0240.0240.0P&I900.01,100.0850.0850.070.080.0LT&D600.0600.0600.0600.020.020.0ADS1,400.01,400.01,350.01,350.0140.0140.0OC&E0.00.00.00.0-80.0-70.0Total6,100.06,700.04,800.04,800.0390.0410.0 CFO Message"In the first three quarters of this fiscal year, we continued to build on the strong performance I shared with you in our last release, with all major financial indicators up year-on-year, especially order intake and business profit," MHI Chief Financial Officer Hiroshi Nishio commented. Nishio continued, "Looking at individual businesses, GTCC drove strong order intake performance, booking 31 large frame gas turbine units mainly in North America and Asia. Demand for gas turbines remains high, particularly in the U.S., as communicated previously. Revenue was up especially in GTCC and Defense & Space, which are both executing some of the largest backlogs ever seen in our history. We also achieved remarkable growth in business profit as we offset one-time expenses in Steam Power with success in other businesses.""On the back of this excellent progress through Q3," Nishio went on, "we have made upward revisions to our full-year order intake, business profit, net income, and FCF guidance. We are entering the final stretch of this fiscal year with renewed confidence, leveraging our historically high backlog to grow profit while continuing to win new orders—the source of future earnings expansion. As we aim to meet these updated targets, we ask our shareholders and other stakeholders to look forward to our next release later this year."Attachment 1: Q1-3 FY2025 Financial ResultsFinancial ResultsAttachment 2: Presentation Materials of Financial ResultsPresentation MaterialsDownloadable PDF of this press releasePress ReleaseNote regarding forward looking statements:Forecasts regarding future performance outlined in these materials are based on judgments made in accordance with information available at the time they were prepared. As such, these projections include risk and uncertainty. Investors are recommended not to depend solely on these projections when making investment decisions. Actual results may vary significantly from these projections due to a number of factors, including, but not limited to, economic trends affecting the Company's operating environment, fluctuations in the value of the Japanese yen to the U.S. dollar and other foreign currencies, and trends in Japan's stock markets. The results projected here should not be construed in any way as a guarantee by the Company.In response to U.S. tariff policy, the Company is pursuing mitigation strategies focused on cost passthroughs. As of the date of this release, the Company expects any impact on performance to be limited in nature.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, Feb 3, 2026 - (ACN Newswire via SeaPRwire.com) – FWD Group Holdings Limited (“FWD Group” or “FWD”) today unveiled findings from its consumer outlook survey, showing that majority of Asia’s middle class feel financially anxious and underprepared for retirement, as rising living costs and growing family responsibilities reshape financial priorities across generations.Nearly three-quarters (71 per cent) of middle-class consumers feel anxiety about their overall financial wellbeing, with top three concerns being the rising cost of everyday living (71 per cent); high cost of healthcare (43 per cent); and unexpected job loss or a reduction in their income (37 per cent). As a result, their primary financial goals are focused on a two-to-three-year time frame. Almost half (44 per cent) of the respondents aim to build a basic safety net for their families, while one-third (37 per cent) hope to achieve financial independence.Lee Yen Ho, Group Chief Distribution and Proposition Officer, FWD Group, said, “It’s clear that there is a shared sense of financial vulnerability across generations of middle classes in Asia. As people live longer and family structures evolve, building the financial resilience to protect loved ones and turn savings into sustainable lifetime income will become increasingly essential. Changing the way people feel about insurance has an important role to play. Insurance provides protection in difficult times, but it can also help to build resilience, secure income for retirement, and give people the confidence they need to celebrate living.”The findings also reveal clear generational pressures: - Generation X (born in 1965-1980) face the toughest balancing act – funding education, paying mortgages and preparing for retirement. Among this segment, 62 per cent worry that their savings won’t keep pace with inflation, and 52 per cent rank guaranteed lifelong income as their top retirement need.- Generation Y (born 1981–1995) juggle multiple financial responsibilities, with 49 per cent worrying about saving for their own retirement. The vast majority (85 per cent) support their parents in addition to caring for their children. Although almost half (47 per cent) are looking for a single, efficient solution to cover multiple family members, most (61 per cent) have never heard of family insurance plans.- Generation Z (born 1996–2010) face growing financial pressure, with 53 per cent expecting difficulties in the next five to 10 years due to rising daily expenses, and 46 per cent saying that insurance products feel too expensive.The pan-Asian survey, conducted with Ipsos, surveyed over 9,000 middle-class consumers aged 21-65 across the 10 markets where FWD operates: Cambodia, Hong Kong SAR, Indonesia, Japan, Macau SAR, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. FWD already offers a range of products across its markets to strengthen protection, resilience, and long-term financial security. For example, in Hong Kong, the One&All medical insurance plan provides flexible family-focused coverage with optional add-on benefits that require no underwriting. In Japan, a single-yen premium annuity product was introduced to meet the growing demand for savings and retirement planning, helping individuals and families build a steady stream of retirement income. In Thailand and Singapore, the FWD Sure pension plan and FWD Invest Flexi Elite plan help customers prepare for retirement through structured income and sustainable wealth-building options. In Indonesia, the FWD Critical First protection plan delivers affordable, inflation-conscious coverage to help families safeguard their financial well-being amid rising costs.About FWD GroupFWD Group (1828.HK) is a pan-Asian life and health insurance business that serves approximately 34 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the main board of the Hong Kong Stock Exchange under the stock code 1828.For more information, please visit www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.comSource: FWD Group Holdings Limited Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Japan, Feb 4, 2026 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. (Honda) today announced plans to co-develop system-on-a-chip (SoC) for its software-defined vehicles (SDVs), with Mythic, a Texas, U.S.-based technology company.Honda has invested in Mythic, which has original technologies and a proven track record in this field of technologies, to establish technologies to enhance the computing performance and energy efficiency of AI to be used for automated driving and other features of its SDVs. Today, Honda announced plans for Honda R&D Co., Ltd., the R&D subsidiary of Honda, to co-develop automobile SoC with Mythic.In order to continue offering the “joy and freedom of mobility” in a sustainable manner, Honda has been placing the highest priority on addressing environmental and safety challenges. In particular, enhanced application of intelligent technology will be the key to addressing safety issues. This makes the advancement of high-performance SoC for SDVs essential; therefore, Honda is conducting research and development of digital computing*1 technologies.Looking ahead, as AI technologies continue to advance, further innovation is required in technologies to enhance computing performance and energy efficiency. With a view to building computing infrastructures which will contribute to the application of next-generation intelligent technologies, Honda is actively exploring neuromorphic*2 SoC technology, that draws inspiration from how the human brain works.Mythic is a startup company with strong expertise in semiconductor technologies that leverage analog computing, which achieves high-efficiency AI processing with low power consumption. For the development of neuromorphic SoC, Mythic has original analog compute-in-memory (CiM)*3 technology and a proven track record in software implementation using tools such as software development kit (SDK)*4. With its analog CiM, Mythic is working to minimize data movement for computation and achieve both high computing performance and energy efficiency.Honda has invested in Mythic to pay close attention to original technologies of Mythic and respond flexibly to future changes in the technological environment and societal trends. Moreover, Honda R&D will leverage its expertise and technologies amassed through the design of its original AI models and the research and development of electronic control units and integrate the original technology of Mythic into AI computing functions that consist of SoC. With that, Honda R&D will further accelerate the research and development of SoC for next-generation SDVs, to further enhance computing performance and energy efficiency.About Mythic- Head office location: Austin, Texas, U.S.A.- Business: Development and sales of neuromorphic NPU*5 for edge computing*6- Representative: Taner Ozcelik, CEO- Establishment: 2012*1 A computing method that repeats computations and data transfers between the processor and memory.*2 A technology that mimics the structure and function of neurons and synapses and integrates computation and memory to eliminate delays in data transfers between the CPU and memory, aiming to enhance computing performance and energy efficiency.*3 A technology that integrates memory and computing units, performing computation directly within memory to significantly reduce power consumption associated with data movement.*4 A development kit that bundles the libraries and tools necessary to develop applications for a specific OS or platform.*5 Neural Processing Unit (NPU): A computing device specialized for AI inference, capable of parallel processing of neural networks.*6 A technology that places data processing infrastructure at or near the devices where data is generated (edge) to process data with minimal latency. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com